Larry Zeitlin
President, Mapp Biopharmaceutical, Inc.
Professional Overview
Larry Zeitlin is an accomplished biopharmaceutical executive with over 20 years of experience leading innovative research and development initiatives. As the President of Mapp Biopharmaceutical, Inc., he oversees the company's strategic vision and operational execution in the discovery and development of novel therapeutic solutions.
Experience Summary
Current Role
As President of Mapp Biopharmaceutical, Inc. since 2004, Larry has been instrumental in driving the company's growth and success. Under his leadership, Mapp has advanced multiple drug candidates through the development pipeline, including two products that have received regulatory approval. Larry is responsible for setting the company's strategic priorities, managing cross-functional teams, and ensuring the delivery of high-quality, safe, and effective biopharmaceutical products.
Career Progression
Prior to joining Mapp, Larry served as a Senior Scientist at Epicyte (later acquired by Biolex), where he played a pivotal role in the development of novel plant-based expression systems for the production of recombinant proteins. His technical expertise and collaborative approach have been integral to his career advancement, allowing him to take on increasingly senior roles and contribute to the success of various biopharmaceutical organizations.
Academic Background
Larry holds a Bachelor of Science degree in Biology from the University of California, San Diego, and a Ph.D. in Molecular Biology from the University of California, Los Angeles. His doctoral research focused on the development of innovative gene expression and protein engineering techniques, laying the foundation for his distinguished career in the biopharmaceutical industry.
Areas of Expertise
- Biopharmaceutical research and development
- Protein engineering and expression systems
- Clinical trial design and execution
- Regulatory affairs and product approvals
- Strategic planning and business development
- Cross-functional team leadership and collaboration
Professional Impact
During his tenure at Mapp Biopharmaceutical, Larry has led the successful development and commercialization of two novel biotherapeutic products, which have had a significant impact on patient care in their respective therapeutic areas. He has also been actively involved in industry associations, serving on the advisory board of CMC Pharmaceuticals, Inc. and the Board of Directors of ServareGMP, where he contributes his expertise to advance the biopharmaceutical industry.
Conclusion
With his extensive experience, technical expertise, and strategic leadership, Larry Zeitlin is a respected biopharmaceutical executive who has consistently delivered results and made meaningful contributions to the industry. As President of Mapp Biopharmaceutical, he continues to drive innovation and positively impact patient lives through the development of cutting-edge biotherapeutic solutions.
